{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T05:03:30Z","timestamp":1787375010257,"version":"build-2736575974"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006390","name":"Universit\u00e9 de Lausanne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006390","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Ovarian cancer (OC) is the primary cause of mortality in women diagnosed with gynecological cancer. Our study assessed pressurized intraperitoneal aerosol chemotherapy (PIPAC) as treatment for peritoneal surface metastases (PSM) from recurrent or progressive OC and conducted survival analyses to identify prognostic factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and methods<\/jats:title><jats:p>This retrospective cohort study, conducted across 18 international centers, analyzed the clinical practices of patients receiving palliative treatment for PSM from OC who underwent PIPAC. All patients were initially treated appropriately outside any clinical trial setting. Feasibility, safety, and morbidity were evaluated along with objective endpoints of oncological response. Multivariate analysis identified prognostic factors for OS and PFS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From 2015-2020, 234 consecutive patients were studied, from which 192 patients were included and stratified by platinum sensitivity for analysis. Patients with early recurrence, within one postoperative month, were excluded. Baseline characteristics were similar between the groups regarding platinum sensitivity (platinum sensitive (PS) and resistant (PR)), but chemotherapy frequency differed, as did PCI before PIPAC. Median PCI decreased in both groups after three cycles of PIPAC (PS 16 vs. 12, p <jats:italic>&amp;lt;<\/jats:italic> 0.001; PR 24 vs. 20, p = 0.009). Overall morbidity was 22%, with few severe complications (4-8%) or mortality (0-3%). Higher pathological response and longer OS (22 vs. 11m, p = 0.012) and PFS (12 vs. 7m, p = 0.033) were observed in the PS group. Multivariate analysis (OS\/PFS) identified ascites (HR 4.02, p <jats:italic>&amp;lt;<\/jats:italic> 0.001\/5.22, p <jats:italic>&amp;lt;<\/jats:italic> 0.001), positive cytology at first PIPAC (HR 3.91, p = 0.002\/1.96, p = 0.035), and <jats:italic>\u2265<\/jats:italic> 3 PIPACs (HR 0.30, p = 0.002\/0.48, p = 0.017) as independent prognostic factors of overall survival\/progression-free survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>With low morbidity and mortality rates, PIPAC is a safe option for palliative treatment of advanced ovarian cancer. Promising results were observed after 3 PIPAC, which did improve the peritoneal burden. However, further research is needed to evaluate the potential role of PIPAC as an independent prognostic factor.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1204886","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T08:55:01Z","timestamp":1692953701000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Descriptive review of current practices and prognostic factors in patients with ovarian cancer treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC): a multicentric, retrospective, cohort of 234 patients"],"prefix":"10.3389","volume":"13","author":[{"given":"Amaniel","family":"Kefleyesus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Escayola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Khomyakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"H\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Reymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Thieme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Sgarbura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Willaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Ceelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Di Giorgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vizzielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Glehen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Robella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoual","family":"Bakrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0637-x","article-title":"An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment","volume":"38","author":"Motohara","year":"2019","journal-title":"Oncogene"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistic","volume":"70","author":"Siegel","year":"2020","journal-title":"CA: A Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds203","article-title":"The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy","volume":"23","author":"Hanker","year":"2012","journal-title":"Ann Oncol"},{"key":"B5","article-title":"Diagnosis and management of ovarian cancer","volume":"93","author":"Doubeni","year":"2016","journal-title":"Am Family Physician"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3802\/jgo.2020.31.e58","article-title":"Incidence and predictors of peritoneal metastases of gynecological origin: a population-based study in the Netherlands","volume":"31","author":"Burg","year":"2020","journal-title":"J Gynecologic Oncol"},{"key":"B7","first-page":"1","volume-title":"Cancer stat facts: ovarian cancer","year":"2022"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6852749","article-title":"Feasibility and safety of pressurized intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis: a retrospective cohort study","volume":"2017","author":"Hu\u00a8 bner","year":"2017","journal-title":"Gastroenterol Res Pract"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30318-3","article-title":"Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications","volume":"20","author":"Alyami","year":"2019","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0000000000001565","article-title":"Pressurized intraperitoneal aerosol chemotherapy, a palliative treatment approach for patients with peritoneal carcinomatosis: description of method and systematic review of literature","volume":"63","author":"Winkler","year":"2020","journal-title":"Dis Colon Rectum"},{"key":"B11","doi-asserted-by":"publisher","first-page":"20180114","DOI":"10.1515\/pp-2018-0114","article-title":"PIPAC-OV3: a multicenter, open-label, randomized, two-arm phase III trial of the effect on progression- free survival of cisplatin and doxorubicin as pressurized intraperitoneal chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistan","volume":"3","author":"Bakrin","year":"2018","journal-title":"Pleura Peritoneum"},{"key":"B12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ygyno.2018.05.001","article-title":"A phase i, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis","volume":"150","author":"Tempfer","year":"2018","journal-title":"Gynecologic Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1515\/pp-2016-0011","article-title":"Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the peritoneal regression grading score (PRGS)","volume":"1","author":"Solass","year":"2016","journal-title":"Pleura Peritoneum"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-013-3213-1","article-title":"Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy","volume":"21","author":"Solass","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2017.03.019","article-title":"Pressurized IntraPeritoneal aerosol chemotherapy \u2013 practical aspects","volume":"43","author":"Hu\u00a8 bner","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2018.02.014","article-title":"Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: an international survey study","volume":"44","author":"Nowacki","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum- resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"New Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/nejmoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"New Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2007.01163.x","article-title":"Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature","volume":"18","author":"Gadducci","year":"2008","journal-title":"Int J Gynecological Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.02.009","article-title":"Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: a phase 2 study","volume":"137","author":"Tempfer","year":"2015","journal-title":"Gynecologic Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/S12957-016-0892-7","article-title":"Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis","volume":"14","author":"Robella","year":"2016","journal-title":"World J Surg Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.10521","article-title":"Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis","volume":"104","author":"Grass","year":"2017","journal-title":"Br J Surg"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2018.04.020","article-title":"Concentrations of cisplatin and doxorubicin in ascites and peritoneal tumor nodules before and after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal metastasis","volume":"44","author":"Tempfer","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.53738\/REVMED.2022.18.782.990","article-title":"Intraperitoneal therapy for carcinomatosis in ovarian cancer: proposed treatment algorithm","volume":"18","author":"Undurraga","year":"2022","journal-title":"Rev Medicale Suisse"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"New Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"20180111","DOI":"10.1515\/pp-2018-0111","article-title":"Pressurized IntraPeritoneal aerosol chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases secondary to platinum resistant ovarian cancer - study protocol for a randomized control trial","volume":"4","author":"Somashekhar","year":"2019","journal-title":"Pleura Peritoneum"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16suppl.5524","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) versus intravenous chemotherapy in unresectable peritoneal metastases secondary to platinum-resistant ovarian cancer: interim analysis of indian randomized control trial","volume":"40","author":"Somashekhar","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1204886\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T08:55:06Z","timestamp":1692953706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1204886\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":32,"alternative-id":["10.3389\/fonc.2023.1204886"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1204886","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,24]]},"article-number":"1204886"}}